Comparison of AstraZeneca and Tvardi Therapeutics Financial Metrics
What happened
A comparison of AstraZeneca and Tvardi Therapeutics showed that AstraZeneca has higher top-line revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio, while it has a higher percentage of institutional ownership at 44.7% compared to AstraZeneca's 20.4%. Analyst consensus targets suggest a potential upside of 32.05% for AstraZeneca and 1,478.95% for Tvardi Therapeutics.
From dailypolitical.com
Why it matters
The comparison highlights differences in valuation and institutional confidence between the two healthcare companies. Tvardi Therapeutics' lower price-to-earnings ratio and higher institutional ownership are noted alongside AstraZeneca's higher revenue and earnings.
From dailypolitical.com
Who's involved
- AstraZenecaA healthcare company being compared based on financial metrics and valuation
Keep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.
- Oracle Corporation and AstraZeneca announced a collaboration to accelerate clinical research.
- Shell overtook HSBC as the most valuable company, while AstraZeneca and Unilever are noted as global peers.
- AstraZeneca presented trial results at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.